Cyclooxygenase-2 inhibitors in lung cancer treatment: Bench to bed.

摘要: The most common and leading cause of cancer-related death in men is lung cancer. Despite the recent advances chemotherapy, advanced cancer still remains incurable. For this, understanding molecular mechanisms involved carcinogenesis necessary to provide potentially effective therapeutic targets for treatment cancer, thus limitations can be overcome. Cyclooxygenase-2 (COX-2) an important inflammation factor that reported up-regulated different cancers. A number COX-2 inhibitors have been developed, but them are restricted due risk factors. Currently, FDA has allowed celecoxib remain on market advised physicians apply this drug with alternative therapies or use at a low dosage. Some other inhibitors, such as, apricoxib etoricoxib under critical investigation currently. Celecoxib being tested clinical trials against as single agent combination agents. Recent studies suggested feasible clinically active regimen patients However, more better role selective prevention along their assessment toxicity. In review, we discussed mechanism actions progression subsequent future management.